| Forside | | Indhold | | Forrige |

Transport af bekæmpelsesmidler over moderkagen, analogier til percutan transport og modellering

Referencer

  1. Akbaraly JP, Leng JJ, Bozler G, Seydel JK. Quantitative relationship between trans-placental transfer physicochemical properties of a series of heterogenous drugs. In: Seydel JK, editor. QSAR and Strategies in the Design of Bioactive Compounds: Proceedings of the Fifth European Symposium on Quantitative Structure-Activity Relationships Bad Segeberg 1984. Weinheim: VCH Verlagsgesellschaft; 1985. p. 313-7. (.
  2. Andersen HR, Nielsen JB, Grandjean P. Toxicologic evidence of developmental neurotoxicity of environmental chemicals. Toxicology. 2000;144(1-3):121-7.
  3. Audus KL. Controlling drug delivery across the placenta. Eur J Pharm Sci. 1999;8:161-5.
  4. Berge WF. Modelling dermal exposure and absorption through the skin 2003.
  5. Borling P, Cohr K-H. Testing/evaluation of DEREK for windows. Hørsholm: Dansk Toksikologi Center; 2001.
  6. Bourget P, Roulet C, Fernandez H. Models for placental transfer studies of drugs. Clin Pharmacokinet. 1995;28(2):161-80.
  7. Carney EW, Scialli AR, Watson RE, DeSesso JM. Mechanisms regulating toxicant disposition to the embryo during early pregnancy: an interspecies comparison. Birth Defects Res C Embryo Today. 2004;72(4):345-60.
  8. Combes R, Gaunt I, Balles M. ATLA. 2004;32:163.
  9. Corley RA, Mast TJ, Carney EW, Rogers JM, Daston GP. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessment. CRC Crit Rev Toxicol. 2003;33(2):137-211.
  10. Cross SE, Magnusson BM, Winckle G, Anissimov Y, Roberts MS. Determination of the effect of lipophilicity on the in vitro permeability and tissue reservoir characteristics of topically applied solutes in human skin layers. J Invest Dermatol. 2003;120(5):759-64.
  11. Engelund EH, Andersen DN, Nielsen AK, Larsen JR, Cohr K-H. Skin penetration. Hørsholm: Dansk Toksikologi Center; 2003.
  12. Flynn GL. Physiochemical determinants of skin absorption. In: Gerrity TR, Henry CJ, editors. Prinicples of route-to-route extrapolation for risk assessment : proceedings of the workshops of route-to-route extrapolation for risk assessment, Hilton Head, S.C. 1990 and Durham, N.C. 1990. New York, N.Y. : Elsevier: 1990. p. 93-127. (.
  13. Frasch HF, Landsittel DP. Regarding the sources of data analyzed with quantitative structure-skin permeability relationship methods (commentary on 'Investigation of the mechanism of flux across human skin in vitro by quantitative structure-permeability relationship'). European journal of pharmaceutical sciences. 2002;15(5):399-403.
  14. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51(1):83-133.
  15. Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH. Placental transporters relvant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther. 2000;294(2):413-20.
  16. Garcia-Bournissen F, Feig DS, Koren G. Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet. 2003;42(4):303-13.
  17. Garland M. Pharmacology of drug transfer across the placenta. Obstet Gynecol Clin. 1998;25(1):21-43.
  18. Grandjean P. Skin penetration. In: Grandjean P, editor. Hazardous chemicals at work. London: Taylor & Francis; 1990. p. 1-187. (.
  19. Gude NM, Roberts CT, Kalionis B, King RB. Growth and function of the normal human placenta. Thrombosis Res. 2004;114:397-407.
  20. Guy RH, Potts RO. Penetration of industrial chemicals across the skin: a predictive model. Am J Ind Med. 1993;23(5):711-9.
  21. Hanke W, Jurewicz J. The risk of adverse reproductive and developmental disorders due to occupational pesticide exposure: an overview of current epidemiological evidence. Int J Occup Med Environ Health. 2004;17(2):223-43.
  22. Harbison RD, Borgert CJ, Teaf CM. Placental metabolism of xenobiotics. In: Sastry BVR, editor. Placental Toxicology. Boca Raton: CRC Press; 1995.(.
  23. Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, et al. A modular approach to the ECVAM principles on test validity. Altern Lab Anim. 2004;32(5):467-72.
  24. Heikkinen T, Ekblad U, Laine K. Placental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. Br J Obstet Gynaecol. 2002;109:1003-8.
  25. Hewitt M, Madden JC, Rowe PH, Cronin MT. Structure-based modelling in reproductive toxicology: (Q)SARs for the placental barrier. SAR QSAR Environ Res. 2007;18(1-2):57-76.
  26. Holmberg RD, Andersen DN. Validering af modeller til forudsigelse af dermal absorption. Hørsholm: Dansk Toksikologi Center; 2004.
  27. Leazer TM, Klaassen CD. The presence of xenobiotic transporters in rat placenta. Drug Metab Dispos. 2003;31(2):153-67.
  28. Lilienblum W, Dekant W, Foth H, Gebel T, Hengstler JG, Kahl R, et al. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH). Arch Toxicol. 2008;82(4):211-36.
  29. Little BB, VanBeveren TT. Placental transfer of selected substances of abuse. Sem Perinatol. 1996;20(2):147-55.
  30. Malassine A, Frendo JL, Evain-Brion D. A comparison of placental development and endocrine functions between the human and mouse model. Hum Reprod Update. 2003;9(6):531-9.
  31. McDonagh AF. Movement of bilirubin and bilirubin conjugates across the placenta. Pediatrics. 2007;119:1032-3.
  32. Miljøstyrelsen. (Q)SAR-modeller. Miljøstyrelsen, København [updated 2007]. Available from: http://www.mst.dk/Kemikalier/Klassificering+og+risikovurdering/QSAR-modeller/.
  33. Miller RK, Wier PJ, Maulik D, di Sant'Agnese PA. Human placenta in vitro: characterization during 12 h of dual perfusion. Contrib Gynecol Obstet. 1985;13:77-84.
  34. Mose T, Kjaerstad MB, Mathiesen L, Nielsen JB, Edelfors S, Knudsen LE. Placental passage of benzoic acid, caffeine, and glyphosate in an ex vivo human perfusion system. J Toxicol Environ Health A. 2008;71(15):984-91.
  35. Mose T, Knudsen LE. Placental perfusion - A human alternative. Altex. 2006;23:358-63.
  36. Mose T, Knudsen LE, Hedegaard M, Mortensen GK. Transplacental transfer of monomethyl phthalate and mono(2-ethylhexyl) phthalate in a human placenta perfusion system. Int J Toxicol. 2007a;26(3):221-9.
  37. Mose T, Mortensen GK, Hedegaard M, Knudsen LE. Phthalate monoesters in perfusate from a dual placenta perfusion system, the placenta and umbilical cord blood. Reprod Toxicol. 2007b;23:83-91.
  38. Moss GP, Dearden JC, Patel H, Cronin MT. Quantitative structure-permeability relationships (QSPRs) for percutaneous absorption. Toxicol in Vitro. 2002;16(3):299-317.
  39. Myllynen P. In search of model for hepatic and placental pharmacokinetics [thesis]. Oulu, Finland: University of Oulu; 2003a.
  40. Myllynen P, Pienimaki P, Jouppila P, Vahakangas K. Transplacental passage of oxcarbazepine and its metabolites in vivo. Epilepsia. 2001;42(11):1482-5.
  41. Myllynen PK, Pienimaki PK, Vahakangas KH. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur J Clin Pharmacol. 2003b;58(10):677-82.
  42. Nielsen JB. Hudpenetration af pesticider - en undersøgelse af effekten af hjælpestoffer, kombinationseffekter, handsker, samt lettere beskadiget hud Miljøstyrelsen; 2008a. 90.
  43. Nielsen JB, Nielsen F. Dermal in vitro penetration of methiocarb, paclobutrazol, and pirimicarb. Occup Environ Med. 2000;57(11):734-7.
  44. Nielsen JB, Nielsen F, Sorensen JA. In vitro percutaneous penetration of five pesticides--effects of molecular weight and solubility characteristics. Ann Occup Hyg. 2004;48(8):697-705.
  45. Nielsen JB, Nielsen F, Sorensen JA. Defense against dermal exposures is only skin deep: significantly increased penetration through slightly damaged skin. Arch Dermatol Res. 2007;299(9):423-31.
  46. Nielsen JB, Sørensen JA, Nielsen F. The usual suspects - influence of physico-chemical properties on lag-time, skin deposition and percutaneous penetration of nine model compounds. J Toxicol Environ Health. 2008b;In press.
  47. Novotna M, Libra A, Kopecky M, Pavek P, Fendrich Z, Semecky V, et al. P-glycoprotein expression and distribution in the rat placenta during pregnancy. Reprod Toxicol. 2004;18(6):785-92.
  48. OECD. Guideline for testing of chemicals, No. 428: Skin Absorption: In vitro Method2003.
  49. Ouchi K, Watanabe S. Measurement of bisphenol A in human urine using liquid chromatography with multi-channel coulometric electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;780(2):365-70.
  50. Pacifici GM. Transfer of antivirals across the human placenta. Early Human Development. 2005;81:647-54.
  51. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clinical Pharmacokinetic Concepts. 1995;28(3):235-69.
  52. Ramsey JD, Woollen BH, Auton TR, Scott RC. The predictive accuracy of in vitro measurements for the dermal absorption of a lipophilic penetrant (fluazifop-butyl) through rat and human skin. Fundam Appl Toxicol. 1994;23(2):230-6.
  53. Reynolds F, Knott C. Pharmacokinetics in pregnancy and placental drug transfer. Oxf Rev Reprod Biol. 1990;11:389-449.
  54. Sartorelli P, Aprea C, Cenni A, Novelli MT, Orsi D, Palmi S, et al. Prediction of percutaneous absorption from physicochemical data: a model based on data of in vitro experiments. Ann Occup Hyg. 1998;42(4):267-76.
  55. Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium, and leucine. Am J Obstet Gynecol. 1972;114(6):822-8.
  56. Schneider H, Huch A. Dual in vitro perfusion of an isolated lobe of human placenta: method and instrumentation. Contrib Gynecol Obstet. 1985;13:40-7.
  57. Shapiro RE. Caffeine and headaches. Neurol Sci. 2007;28 Suppl 2:S179-S183.
  58. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol. 2000;279(4):R1495-R1503.
  59. St-Pierre MV, Stallmach T, Freimoser GA, Dufour JF, Serrano MA, Marin JJ, et al. Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. Am J Physiol Regul Integr Comp Physiol. 2004;287(6):R1505-R1516.
  60. Unadkat JD, Dahlin A, Viyay S. Placental Drug Transfer. Current Drug Metabolism. 2004;5:125-31.
  61. US EPA. Dermal Exposure Assessment: Principles and Applications. Washington DC: US EPA; 1992. (Available from: http://www.epa.gov/opptintr/exposure/presentations/efast/usepa_1992d_dermalea.pdf)
  62. van de Sandt JJ, van Burgsteden JA, Cage S, Carmichael PL, Dick I, Kenyon S, et al. In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study. Regul Toxicol Pharmacol. 2004b;39(3):271-81.
  63. van de Sandt JJ, van Burgsteden JA, Cage S, Carmichael PL, Dick I, Kenyon S, et al. In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study. Regul Toxicol Pharmacol. 2004a;39(3):271-81.
  64. Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. Human exposure to bisphenol A (BPA). Reprod Toxicol. 2007;24(2):139-77.
  65. Volkel W, Colnot T, Csanady GA, Filser JG, Dekant W. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem Res Toxicol. 2002;15(10):1281-7.
  66. Worth AP, van Leeuwen CJ, Hartung T. The prospects for using (Q)SARs in a changing political environment - high expectations and a key role the European Commission's Joint Research Centre. SAR QSAR Environ Res. 2004a;15(5-6):331-43.
  67. Worth AP, Cronin MTD. Report of the workshop on the validation of QSARs and other computational prediction models. ATLA. 2004b;32(Suppl.1):703-6.
  68. Zaretsky MV, Alexander JM, Byrd W, Bawdon RE. Transfer of inflammatory cytokines across the placenta. Am J Obstet Gynecol. 2004;103(3):546-50.

 

| Forside | | Indhold | | Forrige | | Top |



Version 1.0 Juli 2009, © Miljøstyrelsen.